Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

20,666 total articles

FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion

FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion

FuelCell Energy reported Q3 FY2026 results highlighting a substantial increase in its backlog to $3.6 billion driven by new agreements including a major data center power supply contract. The company is progressing its manufacturing facility expansion to target 500 MW annualized capacity by 2028 and aims for positive Adjusted EBITDA by Q4 FY2027. S…

Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense Platform

Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense Platform

Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, has appointed Tzvi Lev as Head of Sales for the Middle East to spearhead commercial expansion across the Gulf Cooperation Council and Israel. Leveraging Lev's extensive defense, diplomatic, and regional market experience, the company aims to convert its advanced autonomous d…

Daktronics, Inc. Announces Fiscal 2027 First Quarter Results

Daktronics, Inc. Announces Fiscal 2027 First Quarter Results

Daktronics, Inc., a leader in digital display technologies, announced fiscal 2027 first quarter results with a 21.2% increase in diluted EPS to $0.40 on 7.1% sales growth, achieving a 10.6% operating margin. The company maintained a product backlog exceeding $300 million for the sixth straight quarter and ended the quarter with a strong cash positi…

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

uniQure has submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K.'s MHRA for its investigational gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The applications are based on three-year Phase I/II study data showing slowed disease progression and the c…

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Lifecore Biomedical has signed a significant agreement to perform tech transfer and commercial manufacturing for a commercially marketed injectable drug product from a global pharmaceutical company. This program, expected to generate revenue starting in 2028, further strengthens Lifecore's late-stage commercial pipeline and expands its customer bas…

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva Pharmaceutical Industries announced positive topline Phase 2a study results for TEV-408, an investigational anti-IL-15 antibody. The drug showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage in celiac disease patients, with a favorable safety profile. TEV-408 also demonstrated a reduction in…

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics, a clinical-stage biotech company focused on precision small molecule medicines for neurological and psychiatric disorders, will participate in upcoming investor events including the Cantor Global Healthcare Conference and TD Cowen Neuropsychiatry Summit. Management will discuss its RAP technology platform and lead drug candida…

WRAP Moves to Operationalize De-Escalation, Advances New BolaWrap 150 Doctrine Toward California POST Certification

WRAP Moves to Operationalize De-Escalation, Advances New BolaWrap 150 Doctrine Toward California POST Certification

Wrap Technologies announced the development of a new law enforcement doctrine and training curriculum designed to operationalize de-escalation utilizing its BolaWrap 150 device, recently classified by the ATF as an instrument of restraint rather than a firearm. The company has submitted the curriculum for independent validation and California Peace…

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma reports that overall survival in its ongoing pivotal Phase III trial of Namodenoson for advanced hepatocellular carcinoma (HCC) is longer than initially expected, prompting plans to advance the interim analysis. While the trial remains blinded, this positive signal may indicate potential clinical benefit for patients with substan…

CoinShares Completes Acquisition of Bastion Asset Management

CoinShares Completes Acquisition of Bastion Asset Management

CoinShares PLC has completed the acquisition of Bastion Asset Management, integrating Bastion's systematic investment team and strategies into its Active Alternative Strategies business. The acquisition enhances CoinShares' ability to offer both passive and active digital asset investment strategies, broadening its institutional platform and produc…

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Opus Genetics announced it will present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 gene therapy targeting BEST1-related inherited retinal diseases. The data presentation is scheduled for September 9, 2026, followed by full clinical datasets at major ophthalmology conferences. OPGx-BEST1 uses an AAV vector to deliver a functiona…

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials, including a clinical pharmacology unit, bioanalytical laboratory, and biospecimen storage facilities in Texas. This acquisition strengthens Fortrea’s integrated clinical development platform from first-in-human studies through Phase …

GXO Announces Participation in Upcoming Investor Conferences

GXO Announces Participation in Upcoming Investor Conferences

GXO Logistics, the world's largest pure-play contract logistics provider, announced that its executive leadership will participate in upcoming investor conferences, including the Jefferies Global Industrials Conference and the Morgan Stanley 14th Annual Laguna Conference. The company will showcase its strategies and business updates through present…

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics announced a strategic reorganization to concentrate resources on developing in vivo engineered TCR-T cell therapies for solid tumors, advancing two candidates toward IND-enabling studies and planned Phase 1 trials by late 2027. Due to insufficient capital, the company has paused enrollment in the Phase 3 ALLOHA-2 study for TSC-10…